Fasenra vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Fasenra | US Daliresp | |
|---|---|---|
| Generic name | benralizumab | roflumilast |
| Drug class | IL-5 Receptor Antagonist (Biologic) | PDE4 Inhibitor (Oral) |
| Treats | Severe eosinophilic asthma | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | AstraZeneca |
| Year approved | 2017 | 2011 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Headache, Sore throat, Allergic reactions, Injection site reactions | Diarrhea, Weight loss, Nausea, Headache |
Frequently asked questions
Is Fasenra or Daliresp better?
Neither is universally "better." Fasenra (benralizumab) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Fasenra and Daliresp?
Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Fasenra has the larger estimated TV advertising budget of the two.